Shopping Cart
Remove All
Your shopping cart is currently empty
Otelixizumab
😃Good
Catalog No. T76754Cas No. 881191-44-2
Alias TRX4, TRX 4, GSK-2136525, GSK2136525, ChAglyCD3
Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases.
Otelixizumab
Otelixizumab
😃Good
Catalog No. T76754Alias TRX4, TRX 4, GSK-2136525, GSK2136525, ChAglyCD3Cas No. 881191-44-2
Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $169 | In Stock | In Stock | |
| 5 mg | $448 | In Stock | In Stock | |
| 10 mg | $715 | - | In Stock | |
| 25 mg | $1,080 | - | In Stock | |
| 50 mg | $1,460 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:97.13% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases. |
| In vitro | Methods: Isolated intrinsic monocyte layer (LPMC) and mucosal tissue explants were incubated with Otelixizumab for 24-48 hours. The production of inflammatory cytokines was determined by enzyme-linked immunosorbent assay. Results: Incubation of LPMC with Otelixizumab reduced the production of interferon gamma, interleukin (IL) -17A, and other inflammatory cytokines and chemokines, while increasing the production of IL-10.[1] |
| In vivo | Human CD3ε chain (nod-HUCdε) transgenic mice treated with Otelixizumab (50 μg/ day, 5 days, intravenously) experienced remission of diabetes symptoms in 47% of mice.[2] |
| Synonyms | TRX4, TRX 4, GSK-2136525, GSK2136525, ChAglyCD3 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CD3 |
| Molecular Weight | 144.58 kDa |
| Cas No. | 881191-44-2 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG1 lambda2 |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Otelixizumab | purchase Otelixizumab | Otelixizumab cost | order Otelixizumab | Otelixizumab in vivo | Otelixizumab in vitro | Otelixizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.